Literature DB >> 31512291

Cytogenetic landscape in 1012 newly diagnosed chronic lymphocytic leukemia.

Amel Senouci1, Thomas Smol2, Sabine Tricot3, Jania Bakala4, Soraya Moulessehoul1, Benoît Quilichini5, Dominique Penther6, Charles Herbaux7, Agnès Daudignon2.   

Abstract

BACKGROUND: Chronic lymphocytic leukemia (CLL) stratification mainly relies on FISH markers according to Döhner's hierarchical model which includes high-risk FISH markers, intermediate FISH, or low-risk FISH. Recently, complex karyotype (CK) has been demonstrated as an independent negative prognostic factor in CLL.
METHODS: A series of 1012 untreated CLL patients have been investigated with both FISH and chromosome banding analysis (CBA) on the same pellet obtained from interleukin IL-2-CPG DSP30 oligonucleotide-stimulated cultured cells.
RESULTS: Combining both FISH and CBA has led to refine prognostic categories with identification of 30% of CK in low-risk and intermediate FISH group. This raises the issue of switching them to a high-risk group. While this series confirmed the significant association between CK and high-risk FISH (P = .003), 33% of CK present no ATM or TP53 deletion. Three groups characterized by significant association between FISH markers and CBA have emerged: CK with TP53 loss and monosomy 15; CK with ATM loss and 14q32 translocation; and CK without ATM or TP53 losses but trisomies 12, 18, and 19 or t(14;18)(q32;q21).
CONCLUSION: We have observed that in addition to FISH analysis, the CBA allows detection of many abnormalities with potential impact on patient follow-up and treatment, mainly CK.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  FISH markers; chronic lymphocytic leukemia; complex karyotype

Mesh:

Substances:

Year:  2019        PMID: 31512291     DOI: 10.1111/ejh.13329

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

Review 1.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

2.  Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia.

Authors:  Zheng Tian; Ming Liu; Xiaosheng Fang; Xiangxiang Zhou; Peipei Li; Ying Li; Lingyan Zhang; Fang Liu; Ya Zhang; Xin Wang
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

Review 3.  Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype.

Authors:  Thomas Chatzikonstantinou; Christos Demosthenous; Panagiotis Baliakas
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.